Preclinical studies have demonstrated that CAR-T cells targeting BCMA or CD19 can effectively deplete autoreactive B cells, alleviating disease symptoms in lupus-prone mouse models [172,173]. The gene discussed is CD19; the disease is systemic lupus erythematosus.